Two recent developments in Alzheimer’s disease research offer new hope for patients living with the disease, and their families. Among those, in June, Tiziana Life Sciences received Food and Drug Administration clearance to use intranasal foralumab in its first patient with moderate Alzheimer’s disease under the FDA’s expanded access investigational new drug program.

FDA clears nasal spray for moderate Alzheimer’s disease in first patient

The president and CEO at Alzheon shared recent insights into neurodegenerative diseases that suggest a single toxic trigger may be responsible for conditions like Alzheimer disease, leading to potential early intervention and treatment strategies. [WATCH TIME: 10 minutes]. WATCH TIME: 10 minutes. "This is the dawn of the new era...

Altering Alzheimer Care Landscape With New, Advanced Therapeutics: Martin Tolar, MD, PhD

A weight loss drug similar to Ozempic could slow down the symptoms of Alzheimer's, according to new research. GLP-1 agonists, a family of treatments that help people manage diabetes, have soared in popularity in large thanks to their ability to also assist people in rapidly losing weight. However, the new findings, which were presented at the Alzheimer’s Association International Conference in Philadelphia last week, suggest that they may have another use.

New 'hope' in cure for Alzheimer's as Ozempic-like drug could slow cognitive decline, study finds

Writers represent independent, third-party users who have joined our contributor program and self-verified their accounts. Writers are expected, like all users, to adhere to our Community Standards.

writer

Kristen Brady

One clinical trial implies that drugs such as Ozempic might possibly be used not only for weight loss and diabetes but to safeguard the brain, and slow the pace at which individuals who have Alzheimer’s lose their capability of thinking clearly, remembering things and performing day-to-day tasks. The outcome needs to be borne out in bigger trials, which are currently underway, before the medication could obtain approval for Alzheimer’s disease.

Beyond Weight Loss: Can Ozempic-like Drug Help With Alzheimer’s?

The US Sun

A SINGLE-dose nasal spray treatment could 'wash away' build ups of toxic proteins associated with Alzheimer’s disease from brain cells and improve memory, scientists say. The study - performed on mice - paves the way for new treatments against Alzheimer's and dementia, researchers at the University of Texas Medical Branch said.

Single-dose nasal spray ‘washes the brain’ of toxic Alzheimer’s proteins – paving the way for breakthrough treatment

In a small study by Imperial College London, presented at the Alzheimer's Association International Conference, researchers found that liraglutide, a GLP-1 agonist and Ozempic precursor, slowed Alzheimer's cognitive decline by 18%, protected brain volume, and reduced inflammation, although the most common side effect was nausea, prompting cautious optimism despite pharmaceutical companies considering the neuroprotective effect of such drugs to be a long shot.

Breakthrough Alzheimer’s Drug: Slowing the Clock on Memory Loss

Health

Medically reviewed by Brigid Dwyer, MDMedically reviewed by Brigid Dwyer, MDDementia is a broad term that describes the loss of cognitive abilities like thinking, remembering, using language, and making decisions. Lewy body dementia (LBD) is one type of dementia, named after the scientist who discovered this variation. This type of dementia is thought to be caused by a buildup of a specific protein in the brain.  There are two types of LBD: dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD). In general, both types of LBD are caused by the same accumulation of protein in the brain and...

Signs and Symptoms of Lewy Body Dementia

It's natural to experience some cognitive decline as we age, but not all cognitive deficits are a result of dementia. There are a variety of hormonal conditions and nutrient deficiencies that can present similar symptoms. If you’re having trouble concentrating or experiencing some memory loss, don’t panic just yet—rule out...

3 Conditions That Cause Cognitive Decline (But Aren't Dementia)

Reuters

(Reuters) -The U.S. Food and Drug Administration has approved the use of Novartis' drug to reduce excess protein in the urine of patients with a type of kidney disease, the health regulator's website showed on Wednesday.

US FDA approves Novartis' kidney disease drug

ScienceAlert


A little-known form of dementia, easily mistaken for Alzheimer's disease, now has a brand new name and specific diagnostic criteria.
Researchers are calling it limbic-predominant amnestic neurodegenerative syndrome (LANS), and they hope that their work makes it easier for medical professionals to care for and counsel patients with various forms of memory loss.



					
			

LANS presents with a different set of brain changes to  Alzheimer's, and it tends to progress slower and with milder symptoms, mostly impacting those over the age of 80.
Similar to Alzheimer's, a definitive diagnosis is only available upon autopsy.
To help those living with memory loss, neurologist Nick Corriveau-Lecavalier...

Scientists Name New Type of Memory Loss Often Mistaken For Alzheimer's

A potential game-changer in Alzheimer’s treatment has emerged from UCLA Health, where scientists have identified a compound that can restore memory function in mice with symptoms of the disease. This groundbreaking discovery, centered around a molecule called DDL-920, could pave the way for a novel approach to treating Alzheimer’s that goes beyond merely slowing the disease’s progression. The study, published in The Proceedings of the National Academy of Sciences, demonstrated that DDL-920 effectively “jumpstarted” the brain’s memory circuitry.

DDL-920: Scientists discover compound that restores lost memories in Alzheimer’s model

Crexont kept symptoms at bay for an extra 30 minutes a day when compared with other Parkinson’s drugs. Amneal Pharmaceuticals Inc. announced yesterday the FDA approval for Parkinson’s drug Crexont (carbidopa and levodopa) via a news release on their website. This novel medication, formerly known as IPX203, combines two common drugs into one capsule.

FDA Approval Granted for Novel Parkinson’s Treatment

Alzheimer's disease is the leading cause of dementia, accounting for 60 to 80% of all dementia cases. And the number of people living with Alzheimer's disease is expected to triple (from 50 million) in less than 30 years. So there's an increasing interest and urgency to better understand the risk...

Research Shows A Connection Between Low Vitamin D & Alzheimer's Disease Risk

The Food and Drug Administration (FDA) on Aug. 6 approved VORANIGO, the first targeted therapy for Grade 2 Isocitrate dehydrogenase (IDH) mutant glioma, a type of brain tumor. Available to patients as a once-daily pill, VORANIGO is the first significant treatment breakthrough in nearly 25 years for Grade 2 IDH mutant glioma, the drug’s maker Servier explained.

FDA approves Servier’s VORANIGO for certain brain tumors

Visual hallucinations are a significant issue for many patients with Parkinson’s disease. A recent study published in the journal Brain reveals that these hallucinations are associated with a marked deficiency of cholinergic activity in specific regions of the brain, particularly the left ventral visual stream and the left superior temporal lobe. This research highlights the importance of cholinergic denervation in visual hallucinations, offering new insights into the underlying mechanisms and potential treatment options.

Visual hallucinations in Parkinson’s disease linked to cholinergic deficiency

As of 2020, about 17.6 million people worldwide have the autoimmune disease rheumatoid arthritis. Past studies have linked rheumatoid arthritis to an increased risk for a number of health concerns. Researchers from the University of Málaga in Spain have now linked rheumatoid arthritis to a greater chance of developing specific...

Why is rheumatoid arthritis tied to a higher risk of cognitive decline?

A new study from Osaka Metropolitan University reveals that antioxidants found in a common brown seaweed may help protect against Parkinson’s disease. This discovery could pave the way for novel preventive strategies against this debilitating neurodegenerative disorder. Ecklonia cava: A Potential Shield for Neurons. Researchers led by Associate Professor...

Preventing Parkinson’s disease may lie in seaweed antioxidants

WAKO, Japan — Scientists at Japan’s RIKEN Center for Brain Science have uncovered a potential new approach to combating Alzheimer’s disease. The research, led by Takaomi Saido and his team, suggests that dopamine – a neurotransmitter often associated with pleasure and reward – might play a crucial role in fighting the devastating effects of this neurodegenerative condition.

Breakthrough in Alzheimer’s research: New dopamine treatment could be the key

J. Souza

A retired military officer who had been struggling with post-traumatic stress disorder (PTSD) tragically died after jumping from the world’s largest cruise ship last month, authorities confirmed.

Cruise Passenger Who Jumped from World's Largest Ship After Dispute Suffered with PTSD

A blood test identified Alzheimer’s disease correctly in older adults with about 90% accuracy. Such tests could help speed the diagnosis of Alzheimer’s disease in primary care clinics and help more people access treatments. An accurate diagnosis of Alzheimer’s disease currently requires either a sample of cerebrospinal fluid...

Accurate blood test for Alzheimer’s disease

NewsBreak

Lomecel-B granted FDA RMAT status for mild Alzheimer’s

The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to Longeveron’s experimental cell therapy Lomecel-B for mild Alzheimer’s disease. The...

Lomecel-B granted FDA RMAT status for mild Alzheimer’s

Comments / 0